Axonics, Inc. (NASDAQ:AXNX) Stock Holdings Raised by Alpine Associates Management Inc.

Alpine Associates Management Inc. grew its position in Axonics, Inc. (NASDAQ:AXNX - Free Report) by 3.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,178,157 shares of the company's stock after purchasing an additional 69,286 shares during the period. Axonics comprises about 6.9% of Alpine Associates Management Inc.'s portfolio, making the stock its 2nd largest position. Alpine Associates Management Inc. owned about 4.26% of Axonics worth $151,600,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Headlands Technologies LLC boosted its stake in Axonics by 162.1% in the second quarter. Headlands Technologies LLC now owns 2,928 shares of the company's stock valued at $197,000 after acquiring an additional 1,811 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in Axonics during the first quarter valued at $218,000. Xponance Inc. grew its holdings in Axonics by 7.5% during the second quarter. Xponance Inc. now owns 3,231 shares of the company's stock valued at $217,000 after purchasing an additional 225 shares during the period. Entropy Technologies LP purchased a new stake in Axonics in the third quarter worth $395,000. Finally, Mercer Global Advisors Inc. ADV raised its stake in shares of Axonics by 12.7% in the second quarter. Mercer Global Advisors Inc. ADV now owns 6,981 shares of the company's stock valued at $469,000 after buying an additional 785 shares during the period. 99.48% of the stock is owned by institutional investors.

Insider Activity

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of the firm's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total value of $205,523.01. Following the sale, the chief financial officer now owns 40,362 shares of the company's stock, valued at $2,801,526.42. This trade represents a 6.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.85% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a "hold" rating on shares of Axonics in a report on Friday, November 8th. Eight research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $71.00.

Axonics Stock Performance

AXNX remained flat at $70.98 during trading on Wednesday. Axonics, Inc. has a 12-month low of $55.09 and a 12-month high of $71.05. The firm has a 50 day moving average price of $69.95 and a 200 day moving average price of $68.65. The firm has a market cap of $3.63 billion, a price-to-earnings ratio of -591.45 and a beta of 0.82.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.